Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Talquetamab in relapsed/refractory multiple myeloma: Extended follow-up from MonumenTAL-1 and interventions for GPRC5D-related toxicities
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer
Understanding How On-Target and Off-Target ADC Toxicities Work
Monitoring for Infection-Like AEs Is Essential for CIML NK in GI Cancers
Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC